



PATENT
Customer No. 22,852
Attorney Docket No. 06478.1491

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Klaus PREISSNER et al.) Group Art Unit: Not Assigned
)
Application No.: 10/631,896) Examiner: Not Assigned
)
Filed: August 1, 2003)
)
For: PHARMACEUTICAL)
PREPARATION WITH RNA AS)
HEMOSTASIS COFACTOR)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.


Dated: November 18, 2003

By: 
Carol P. Einaudi
Reg. No. 32,220

610105_1

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



INFORMATION DISCLOSURE CITATION

App. No.	06478. 1491	Appln. No.	10/631,896
Applicant	Klaus PREISSNER et al.		
Filing Date	August 1, 2003	Group:	Not Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,141,849	08/25/92	Chou	435	6	

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
02/096926 A1	12/05/02	WIPO			
01/73003 A1	10/04/01	WIPO			
01/08634 A2	02/08/01	WIPO			
01/00829 A2	01/04/01	WIPO			
98/51335	11/19/98	WIPO			
0 670 165 A2	09/06/95	Europe			
0 288 306 A1	10/26/88	Europe			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Buiko et al., "Rapid Treatment of Virus-Based Pneumonia in Young Children by Controlled Use of Immunoglobulin and Spaced Ribonuclease Inhalation," Derwent Abstract XP002255128 (1986).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

610088_1